Pfizer completes acquisition of Metsera

Pfizer (PFE) announced the successful completion of its acquisition of Metsera (MTSR). “Pfizer has completed its acquisition of all outstanding shares of common stock of Metsera for $65.60 per share in cash, representing an enterprise value of approximately $7.0 billion, plus a contingent value right of up to $20.65 per share in potential additional payments tied to the achievement of three specified clinical and regulatory milestones. Metsera is now a wholly owned subsidiary of Pfizer. In connection with the acquisition, Metsera’s shares of common stock will cease trading on the NASDAQ Global Select Market following the close of market today. As previously disclosed, the transaction is expected to be dilutive through 2030, primarily to enable further investment in several promising late-stage pipeline candidates. Updated impact to Pfizer’s financial outlook will be provided in conjunction with its 2026 guidance expected later this year,” the company stated. “This strategic milestone represents more than a transaction-it’s a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it. We look forward to combining Metsera’s innovative portfolio with our global development, manufacturing and commercial infrastructure. Working with our talented new colleagues from Metsera, we will advance our shared goal of accelerating and bringing these important candidate therapies to patients around the world,” added Albert Bourla, Pfizer Chairman and Chief Executive Officer.